Literature DB >> 31184980

Acute respiratory failure due to eosinophilic pneumonia following pneumococcal vaccination.

Ryota Kikuchi1, Yuki Iwai1, Yusuke Watanabe1, Hiroyuki Nakamura1, Kazutetsu Aoshiba1.   

Abstract

A 68-year-old woman under maintenance hemodialysis was admitted to our hospital with fever and dyspnea that had developed two days after the second vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23). She had received the first vaccination with PPV23 five years earlier without any complications. Chest X-ray and computed tomography (CT) showed bilateral diffuse infiltrative and ground glass opacities. Bronchoalveolar lavage (BAL) revealed an abundance of eosinophils. A positive test result for PPV23 was obtained in the drug lymphocyte stimulation test. The patient was diagnosed as having eosinophilic pneumonia caused by the pneumococcal vaccination and was successfully treated by 3-week's administration of a steroid. No disease recurrence was observed at the three-month follow-up. Thus, EP is a rare, but life-threating condition following pneumococcal vaccination.

Entities:  

Keywords:  Pneumococcal vaccine; eosinophilic pneumonia; respiratory insufficiency

Mesh:

Substances:

Year:  2019        PMID: 31184980      PMCID: PMC6930081          DOI: 10.1080/21645515.2019.1631134

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  7 in total

1.  Lymphocyte transformation test for medicinal herbs yields false-positive results for first-visit patients.

Authors:  Naoki Mantani; Toshiaki Kogure; Jun'ichi Tamura; Yutaka Shimada; Katsutoshi Terasawa
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

2.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 3.  Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines.

Authors:  M R Hilleman; A J Carlson; A A McLean; P P Vella; R E Weibel; A F Woodhour
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

4.  Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.

Authors:  Nirma Khatri Vadlamudi; Kamalpreet Parhar; Kim Lorenzo Altre Malana; Amy Kang; Fawziah Marra
Journal:  Vaccine       Date:  2019-01-23       Impact factor: 3.641

5.  Safety of revaccination with pneumococcal polysaccharide vaccine.

Authors:  L A Jackson; P Benson; V P Sneller; J C Butler; R S Thompson; R T Chen; L S Lewis; G Carlone; F DeStefano; P Holder; T Lezhava; W W Williams
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

6.  Acute respiratory failure secondary to eosinophilic pneumonia following influenza vaccination in an elderly man with chronic obstructive pulmonary disease.

Authors:  Prapaporn Pornsuriyasak; Thitiporn Suwatanapongched; Jettanong Klaewsongkram; Supranee Buranapraditkun; Porpon Rotjanapan
Journal:  Int J Infect Dis       Date:  2014-06-27       Impact factor: 3.623

Review 7.  Aluminum Adjuvant-Containing Vaccines in the Context of the Hygiene Hypothesis: A Risk Factor for Eosinophilia and Allergy in a Genetically Susceptible Subpopulation?

Authors:  Todd D Terhune; Richard C Deth
Journal:  Int J Environ Res Public Health       Date:  2018-05-03       Impact factor: 3.390

  7 in total
  1 in total

1.  Acute Eosinophilic Pneumonia Following mRNA COVID-19 Vaccination: A Case Report.

Authors:  Miguel Barrio Piqueras; Ana Ezponda; Carmen Felgueroso; Cesar Urtasun; Isberling Madeleine Di Frisco; Javier Carlos Larrache; Gorka Bastarrika; Ana Belén Alcaide
Journal:  Arch Bronconeumol       Date:  2021-11-16       Impact factor: 6.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.